title: [Effect of statin therapy on mortality in patients with non-ischemic dilated cardiomyopathy].
abstract: OBJECTIVE
  To explore the effect of early statin therapy (atorvastatin and simvastatin) on mortality in patients with non-ischemic dilated cardiomyopathy.
  
  
  METHODS
  A retrospective study was conducted at a single center. A total of 315 patients with non-ischemic dilated cardiomyopathy, admitted into our hospital from January 2002 to December 2008, were enrolled. The association of statin therapy at the initial hospitalization with all-cause mortality was evaluated. The median follow-up period was 45.1 months.
  
  
  RESULTS
  By the single-factor analysis, we found that the follow-up mortality was 17.2% in statin group and it was significantly lower than 37.4% of non-statin users (P = 0.003); in patients with worsening cardiac function NYHA III - IV, the mortality of statin group was 17.2% while a much higher mortality of 47.4% was found in non-statin users (P = 0.003); in patients with NYHA I - II, no significant difference was found in mortality between two groups. By the multi-factor analysis adjusting for age, gender, history of hypertension, diabetes mellitus, current cigarette smoking, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, left ventricular ejection fraction, NYHA functional class, use of angiotensin-converting enzyme inhibitor, β blocker, aldosterone, other diuretics, digoxin and calcium channel blocker, we found the relative risk (RR) of death in statin use was 0.352 (95%CI 0.135 - 0.920, P = 0.033). In patients with NYHA III - IV, the relative death risk of statin therapy was 0.250 (95%CI 0.081 - 0.778, P = 0.017).
  
  
  CONCLUSIONS
  Early treatment of atorvastatin or simvastatin is closely correlated with the reduction of mortality in non-ischemic dilated cardiomyopathy patients, especially in those with severe heart failure. And the correlation is independent of the lipid-lowering effects of statins, ACEI and β-blocker therapy.
authors.affiliation: Department of Cardiology, Beijing Anzhen Hospital, Capital University of Medical Science, Beijing 100029, China.
authors.forename: Xu
authors.initials: X
authors.lastname: Li
authors.forename: Xing-peng
authors.initials: XP
authors.lastname: Liu
authors.forename: Xiao-hui
authors.initials: XH
authors.lastname: Liu
authors.forename: Xin
authors.initials: X
authors.lastname: Du
authors.forename: Jun-ping
authors.initials: JP
authors.lastname: Kang
authors.forename: Qiang
authors.initials: Q
authors.lastname: Lü
authors.forename: Hai-yun
authors.initials: HY
authors.lastname: Wang
authors.forename: Xia
authors.initials: X
authors.lastname: Xu
authors.forename: Cui
authors.initials: C
authors.lastname: Liang
authors.forename: Qian
authors.initials: Q
authors.lastname: Yan
authors.forename: Tao
authors.initials: T
authors.lastname: Lei
authors.forename: Li-li
authors.initials: LL
authors.lastname: Geng
authors.forename: Bai-qiu
authors.initials: BQ
authors.lastname: Liu
authors.forename: Chang-sheng
authors.initials: CS
authors.lastname: Ma
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D002311:Cardiomyopathy, Dilated / Q000188:drug therapy* / Q000401:mortality*; D005260:Female; D006333:Heart Failure / Q000188:drug therapy / Q000401:mortality; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D000319:Adrenergic beta-Antagonists; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors